Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company. It engages in developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. The company was founded in 2020 and is headquartered in Cambridge, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
72
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Hemab Therapeutics Holdings Inc. market cap is $1.86B.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Hemab Therapeutics Holdings Inc. 52 week high is $55.42 as of November 20, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Hemab Therapeutics Holdings Inc. 52 week low is $18.00 as of November 20, 2026.
Hemab Therapeutics Holdings Inc. stock price today is $39.29.
Hemab Therapeutics Holdings Inc. stock price yesterday was $39.86.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Hemab Therapeutics Holdings Inc. P/B ratio is 4.3375.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Hemab Therapeutics Holdings Inc. 50-day moving average is $36.72.
Hemab Therapeutics Holdings Inc. has 72 employees.